Items where authors include "Middleton, M.R."

Article

Urbonas, V., Schadendorf, D., Zimmer, L. et al. (11 more authors) (2019) Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology, 30 (2). pp. 317-324. ISSN 0923-7534

Corrie, P.G., Marshall, A., Nathan, P.D. et al. (36 more authors) (2018) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 29 (8). pp. 1843-1852.

Woodcock, V.K., Clive, S., Wilson, R.H. et al. (11 more authors) (2018) A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 118 (6). pp. 770-776. ISSN 0007-0920

Ahmad, S.S., Qian, W., Ellis, S. et al. (26 more authors) (2015) Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Research, 25 (5). pp. 432-442. ISSN 0960-8931

Corrie, P., Marshall, A., Dunn, J. et al. (17 more authors) (2014) Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, 15 (6). pp. 620-630. ISSN 1470-2045